Pharma CEOs more confident than leaders of other industries

A third of pharmaceutical industry CEOs are very confident that they can increase their companies' revenues over the next 12 months, according to PricewaterhouseCoopers 12th annual CEO survey.

The survey of 47 pharma CEOs around the world indicates that the credit crunch may actually provide opportunities for many large pharma companies, particularly those with low debt ratios and strong cash positions.

Compared to over a thousand CEOs interviewed in other industry sectors, pharma CEOs are more confident and less concerned about the disruption of capital markets than their peers are, less likely to state that recent problems in the global banking system will delay investment plans, and more likely to be using internally generated cash flow as a means of financing growth.

Continuing merger activity looks likely, with pharma companies using their healthy cash balances to fund acquisitions. Pharma CEOs are more likely than their peers in other industry sectors to be planning a cross-border merger or acquisition in the next 12 months.

John Kelly, PwC Partner for Pharma in Ireland said:

“Pharma leaders including those in Ireland will have to make tough decisions about what actions are required to ensure their company’s future growth and successful operating models. Historically, external economic forces have impacted the pharmaceutical sector less than other manufacturing areas, and this year pharma CEOs are notably more confident about short-term growth than their peers. However weak pipelines require CEOs to look hard at their cost base and business structures.

“The economic downturn has created a potentially beneficial environment for large pharma companies, including those operating in Ireland, wanting to expand and build on their R&D base. For instance in the current climate, with the yen rising against the US dollar and the euro, Japanese companies are potentially well placed to go on a buying spree for US, European pharma and biotech.”

Despite challenges such as the downturn, over-regulation and low-cost competition, 55% of pharmaceutical CEOs believe that the structural changes facing the industry's business model will have a positive impact over the long term.

ENDS

Note to editor:

For more details or a copy of the report please visit www.pwc.com/ceosurvey

About PricewaterhouseCoopersPricewaterhouseCoopers (www.pwc.com) provides industry-focused assurance, tax and advisory services to build public trust and enhance value for its clients and their stakeholders. More than 155,000 people in 153 countries across our network share their thinking, experience and solutions to develop fresh perspectives and practical advice.

"PricewaterhouseCoopers" refers to the network of member firms of PricewaterhouseCoopers International Limited, each of which is a separate and independent legal entity.